AAV-AQP1 is under clinical development by MeiraGTx and currently in Phase II for Xerostomia. According to GlobalData, Phase II drugs for Xerostomia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AAV-AQP1 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AAV-AQP1 overview
AAV-AQP1 is under development for the treatment of xerostomia resulting from the use of ionizing radiation in the treatment of head and neck cancer and xerostomia associated with Sjogren’s syndrome. The drug candidate is administered slowly into the single parotid salivary gland. It consists of adeno-associated virus vector serotype 2 containing the human aquaporin-1 gene (AAV2hAQP1). The therapeutic candidate is developed based on synthetic biology and gene regulation platform.
MeiraGTx overview
MeiraGTx is a gene therapy company that develops treatments for ocular, salivary gland and central nervous system diseases. It is investigating AAV-RPGR program against X-linked retinitis pigmentosa (XLRP); AAV-RPE65 gene therapy to treat RPE65 (retinal pigment epithelium-specific 65 kDa) gene deficiency; AAV-CNGB3 drug for achromatopsia (ACHM); and A006 program targeting wet AMD (age-related macular degeneration). The company is also evaluating AAV-GAD medicine to treat Parkinson’s disease; AAV-UPF1 against amyotrophic lateral sclerosis (ALS); AAV-AQP1 for radiation-induced xerostomia (RIX); and AAV-AQP1 program to treat xerostomia caused due to Sjogren’s syndrome. MeiraGTx is developing riboswitch inducible expression programs targeting ophthalmology and oncology indications, diabetes and metabolic disorders, among others. The company operates in the UK, and the Netherlands. MeiraGTx is headquartered in New York City, New York, the US.
For a complete picture of AAV-AQP1’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
